Tenet Healthcare enters the second week of August with a striking divergence: shorts have quietly stepped back 30% over the past month, while the stock has ripped 25% higher, and an almost unanimous analyst community is scrambling to raise targets in the wake of a blowout earnings print.
The post-earnings repricing is the story here. When Tenet reported on July 23, the stock jumped 19-22% on the day and extended to a 28-29% five-day gain — one of the sharpest post-print moves in recent memory for a company this size. The week ending August 8 adds another 2.9%, pushing the close to $262. That kind of sustained momentum after a gap move tells you covering activity, not just fresh longs, is doing some of the work.
Options positioning corroborates that the crowd is no longer defensive. The put/call ratio has dropped to 1.25 — more than two standard deviations below its 20-day average of 1.36 — meaning the level of put-buying that characterized much of July has unwound sharply. A month ago PCR was running at 1.49 and above; the recent compression toward more balanced territory matches the short covering narrative. Borrow conditions remain entirely relaxed: availability is exceptionally loose at nearly 3,710% of short interest, and the cost to borrow has eased 18% on the week to a negligible 0.37%. With 78 million shares still available in the lending pool, there is no squeeze dynamic and no dislocation in the lending market. Short interest itself has declined from around 4 million shares in early July to roughly 2.8 million — about 3.2% of the free float — confirming that the structural short thesis has lost adherents without yet disappearing entirely.
The Street's reaction to earnings was nearly unanimous, and the upgrades in targets are material. Wells Fargo lifted its target from $231 to $281, maintaining Overweight, just this week. In the days immediately following the print, Morgan Stanley moved to $274, UBS to $308, RBC to $283, Truist to $290, and Guggenheim to $283 — all maintaining Buy or equivalent ratings. The consensus mean target now sits at $282, implying only about 7% upside from current levels. That math matters: the stock has essentially caught up to where the Street thought it would be, which historically shifts the debate from "does this deserve a higher multiple" to "what does the next leg require." On valuation, the trailing P/E has expanded to 12.3x over the past month alongside a 3-point move in book value multiples — still not demanding for a healthcare facilities operator, but no longer the deep-value setup that drew initial buyers. EV/EBITDA of 7.5x has actually compressed slightly over the same period, keeping enterprise-level valuations in check. Tenet's EPS surprise factor score ranks in the 93rd percentile, the standout metric on a scorecard that is otherwise middling — short score rank of 57, utilization rank of 77, analyst recommendation differentiation of just 5.
The bull case rests on USPI: the ambulatory surgery unit is growing faster, earns higher margins, and generates better returns on capital than the acute care hospitals. Equity earnings from the segment are expected to rise through 2026. Bears point to a concrete near-term risk — the anticipated expiration of ACA-era subsidies, which analysts estimate could strip coverage from 80-85% of patients in affected markets, creating up to a $220 million headwind to the Acute segment and $30 million to USPI. A $148 million one-time Medicaid state fund receipt in the recent quarter inflated results and adds a sustainability question to the headline beat. Insider activity leans in the same cautious direction: the COO sold $2.6 million of stock on July 29 at $258, and several directors liquidated positions around $244-244 in the days immediately following the earnings gap — collectively over $7 million in sales at prices well above where the stock traded in June.
The key question for the weeks ahead is whether Tenet can hold near its consensus price target while the market digests both the subsidy risk and a modest wave of insider sales — and whether USPI guidance through the rest of 2026 continues to support the margin expansion story that drove the July re-rating.
See the live data behind this article on ORTEX.
Open THC on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
